Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge

OBJECTIVE: The aim of this observational study was to determine the optimal timing of interleukin-6 receptor inhibitor (IL6ri) administration for coronavirus disease 2019 (COVID-19). METHODS: Patients with COVID-19 were given an IL6ri (sarilumab or tocilizumab) based on iteratively reviewed guidelin...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Int J Infect Dis
Main Authors: Sinha, Pranay, Mostaghim, Anahita, Bielick, Catherine G., McLaughlin, Angela, Hamer, Davidson H., Wetzler, Lee M., Bhadelia, Nahid, Fagan, Maura A., Linas, Benjamin P., Assoumou, Sabrina A., Ieong, Michael H., Lin, Nina H., Cooper, Ellen R., Brade, Karrine D., White, Laura F., Barlam, Tamar F., Sagar, Manish
Formato: Artigo
Idioma:Inglês
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7591937/
https://ncbi.nlm.nih.gov/pubmed/32721528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijid.2020.07.023
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares